Company
APTA -4.49%Aptamer Group plc
Market Cap: £2.9 Million
GBP as of Aug 2, 2026 | US$3.8 Million
$APTA -4.49% $APTA United Kingdom Healthcare Biotechnology UK Healthcare UK BiotechnologyAptamer Group plc Market Capitalization Over Time
View HistoryEvolution of Aptamer Group plc market cap in the past 5 years
Market capitalizations are calculated from the opening stock price at the beginning of each month.
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $209.25 B |
| Vertex Pharmaceuticals | $121.09 B |
| Regeneron Pharmaceuticals | $78.52 B |
| argenx | $52.93 B |
| Beigene Ltd. | $51.33 B |
Sector: Healthcare
| Company | Market Cap (USD) |
|---|---|
| Lilly | $1.024 T |
| Johnson & Johnson | $617.78 B |
| AbbVie | $443.36 B |
| Roche | $418.93 B |
| UnitedHealth Group | $376.34 B |
Detailed Description
Aptamer Group plc provides binders for research, diagnostics, and therapeutics in the United Kingdom, rest of Europe, and internationally. The company offers Optimer platform that enables the discovery and development of oligonucleotide binders; custom development services for oligonucleotide-based aptamer and Optimer binders; solutions to bioprocessing, diagnostic, and pharmaceutical scientists; and contract research services in the field of therapeutics. It serves pharma companies, diagnostic development companies, and research institutes. Aptamer Group plc was founded in 2008 and is headquartered in York, the United Kingdom.
Financials
| Last Financial Reports Date | None |
| Revenue TTM | £None |
| EBITDA | £None |
| Gross Profit TTM | £None |
| Profit Margin | % |
| Operating Margin | % |
| Quarterly Revenue Growth | % |